Press "Enter" to skip to content

Cofepris warns consumers warning about illegal Molnupiravir oral treatment

Mexico City, Mexico — The Federal Commission for the Protection against Sanitary Risks (Cofepris) is warning consumers about the illegal marketing of Molnupiravir. The pill is used as an oral treatment for covid-19 symptoms.

The health agency says they have received information about the illegal marketing of the product in Mexico. La Comisión Federal para la Protección contra Riesgos Sanitarios (Cofepris) says the product is being offered in a 40-capsule bottle of 200 mg. They say the drug requires a prescription for dispensing.

Earlier this month, Molnupiravir was authorized for emergency use for the treatment of COVID-19, but only for use in public institutions of the federal and state governments that make up the National Health System.

In their statement, Cofepris says that to date, there is no record of imports of the medication, so any product marketed in Mexico is considered illegal and its consumption implies health risks.

Some of the products marketed that do not have authorization are identified with the brands MOLAZ from the Azista laboratory, white box with orange and purple lines, containing 200 mg capsules, which is offered as an over-the-counter product

MPIRAVIR from the Merit laboratory, white box with green color, yellow lines with expiration date 10/2023 containing 40 capsules of 200 mg.